Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TRACK-NK cells |
| Synonyms | |
| Therapy Description |
TRACK-NK cells are umbilical cord blood-derived natural killer (NK) cells engineered to express soluble IL-15 and CD274 (PD-L1), which potentially induce cytotoxicity against tumor cells and decrease tumor growth (PMID: 38572955, PMID: 39903538). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TRACK-NK cells | TRACK NK cells|sIL15_TRACK NK cells|COH06 | TRACK-NK cells are umbilical cord blood-derived natural killer (NK) cells engineered to express soluble IL-15 and CD274 (PD-L1), which potentially induce cytotoxicity against tumor cells and decrease tumor growth (PMID: 38572955, PMID: 39903538). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05334329 | Phase I | Cyclophosphamide + Fludarabine Atezolizumab TRACK-NK cells | Genetically Engineered Cells (COH06) With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors | Active, not recruiting | USA | 0 |